-40.9%
TSCO vs MRNA
+511.3%
-552.2%
-51.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | -2.2% | +3.4% | +1.2% |
| 7D | +0.8% | +5.5% | -4.7% | +0.7% |
| 30D | +5.5% | +158.7% | -153.3% | +2.8% |
| 3M | +20.0% | +182.1% | -162.2% | +16.1% |
| 6M | -29.8% | +151.8% | -181.6% | -31.7% |
| YTD | -28.7% | +393.6% | -422.2% | -33.3% |
| 1Y | -40.9% | +499.5% | -540.4% | -45.0% |
| All | -40.9% | +511.3% | -552.2% | -45.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling